MetaCap

BeyondSpring (BYSI) vs Seres Therapeutics (MCRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BeyondSpring is the larger company by market cap ($13.7 million vs $12.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BYSI-48.80%MCRB-54.41%
+29%-15%-58%
Oct 7, 20261 yearNov 20, 2026
BYSI-45.51%MCRB-54.24%
+9%-24%-57%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BYSI versus MCRB key metrics
MetricBYSIMCRB
Share price$0.33$1.24
Market cap$13.66M$12.64M
1-day change-24.49%-6.77%
YTD return-79.75%—
1-year return-82.77%—
5-year return-97.70%—
EPS (TTM)$-0.20$-5.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$789.00K
Net income (latest FY)$-1.01M$5.70M
Operating margin—-11910.14%
Net margin—721.93%
52-week high$2.44$18.86
52-week low$0.299$1.20
Distance from 52-week high-86.48%-93.43%
Analyst consensus—none
Avg. price target upside—+1270.97%
Average volume261.79K74.83K
Shares outstanding41.41M10.20M
Employees4466
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BeyondSpring

BYSI stock →

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About Seres Therapeutics

MCRB stock →

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

BYSI vs MCRB FAQ

Which is bigger, BeyondSpring or Seres Therapeutics?

BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $12.64M for Seres Therapeutics (MCRB).

Are BeyondSpring and Seres Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons